|View printer-friendly version|
Pharmaceutical Industry Leader J. Martin Carroll Elected Chairperson as
of 2016 Annual Meeting; Argeris Karabelas, Ph.D., and
“We are excited to have Mr. Carroll join Inotek’s Board. Over the past year we have named four outstanding executives to our Board, and Marty’s experience will significantly complement their expertise,” said David P. Southwell, President and Chief Executive Officer of Inotek. “Mr. Carroll has a track record of success as a pharmaceutical industry leader and will bring operational experience in many areas including R&D, manufacturing and sales. His diverse expertise will be invaluable to us as we further develop Inotek into a leading ophthalmology company. As our venture capitalists step off the Board, I would like to thank them for their longstanding support of Inotek.”
Mr. Carroll most recently led Global Strategy and Development for
“I am pleased to join the Board of Inotek during an exciting time. The Company’s world class leadership team and Board of Directors demonstrates their commitment to bring novel ocular therapies to market for patients. I look forward to working closely with Inotek’s management and Board,” said Mr. Carroll.
Argeris Karabelas, Ph.D., currently Chairperson of the Board, announced
his resignation from the Board of Directors effective as of the 2016
Annual Meeting. Mr.
“Inotek has made the transition from research to late stage development with the addition of experienced professionals to our skilled staff. The changes at the Board are designed to strengthen the domain and industry experience in commercial execution to prepare Inotek for its next phase. We are excited to have attracted and engaged such accomplished talent,” said Dr. Karabelas.
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These forward-looking statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Inotek Pharmaceuticals Corporation
Claudine Prowse, Ph.D., 718-552-4305
Vice President, Strategy and Investor Relations Officer